← SEC 公告列表 | AMIX SEC 公告 | Autonomix Medical, Inc.（AMIX）

重大事件 即時報告 8-K 2026-07-28

Autonomix Medical 8-K申報 披露現金約510萬美元及股本更新

於 SEC 網站開啟原文

AI 繁中摘要

8-K 申報｜Autonomix Medical 更新現金狀況 📊 美國納斯達克上市公司 Autonomix Medical, Inc.（股票代碼：AMIX）於 2026 年 7 月 28 日向 SEC 提交 8-K 申報，披露最新現金餘額及股本數據。 截至 2026 年 7 月 28 日，公司現金約為 510 萬美元；已發行普通股總數為 971,043 股，當中包括近期於 2026 年 7 月 13 日透過認股權證誘因計劃所發行的股份。 是次申報僅為更新財務狀況，未提及管理層展望或具體業務進展。對於投資者而言，現金儲備約 500 萬美元水平，結合近 100 萬股的流通股本，反映公司仍處於早期階段，資金運用及股權攤薄情況值得關注。
展開英文正文 
amix20260728_8k.htm
 

 
 

false
0001617867

0001617867

2026-07-28
2026-07-28

  

 UNITED STATES
 

 SECURITIES AND EXCHANGE COMMISSION
 

 Washington, D.C. 20549
 

  

  

 FORM 8-K
 

  

 CURRENT REPORT
 

 Pursuant to Section 13 or 15(d) of the
 

 Securities Exchange Act of 1934
 

  

 Date of Report (Date of earliest event reported): July 28, 2026
 

  

 
 
 

  

  

 Autonomix Medical, Inc.
 

 (Exact name of registrant as specified in its charter)

  

 
 Delaware
001-41940
47-1607810

 

 (State or other jurisdiction of
incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)

 

 
  

 21 Waterway Avenue, Suite 300
 

 The Woodlands, TX 77380
 

 (Address of principal executive offices) (Zip Code)

  

 Registrant’s telephone number, including area code: (713) 588-6150
 

  

 Not Applicable
 

 (Former Name or Former Address, if Changed Since Last Report)

  

  

 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

  

 
  
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 
  

 
  
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 
  

 
  
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 
  

 
  
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
  

 Securities registered pursuant to Section 12(b) of the Act:
 

  

 
 Title of Each Class
Trading Symbol(s)
Name of Each Exchange on which Registered

 

 Common Stock, par value $0.001 per share
AMIX
The Nasdaq Stock Market LLC

 

 
  

 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

  

 Emerging growth company ☒
 

  

 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.               ☐
 

  

 
 

 
 

 

  

 Item 8.01. Other Events
 

  

 As of July 28, 2026, Autonomix Medical, Inc.’s (the “Company”) cash balance is approximately $5.1 million and shares of the Company’s common stock outstanding is 971,043, including shares of common stock issued as part of the Company’s recent warrant inducement from July 13, 2026.

  

  

 Signature
 

  

 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

  

 
  
AUTONOMIX MEDICAL, INC.
 

 

  
 
 
 

 

  
 
 
 

 

  
By:
/s/ Trent Smith
 

 

  
 
Trent Smith
 

 

  
 
Chief Financial Officer
 

 

 
  

  

 Dated: July 28, 2026